APLNR and neoplasm: The screening assay was capable of studying how effector T cells respond to genetically manipulated tumor cells and it was demonstrated in vivo that multiple mutations in APLNR genes related to cellular signaling could sensitize the tumor toward ACT immunotherapy.[72] In terms of checkpoint blockade therapies, low response rates suggest the need for the discovery of novel targets.